Abstract
Leukemia has been treated with chemotherapy for the past 40 years with only moderate success. A growing body of evidence suggests that by augmenting the immune system more effective results may be obtained. This is highlighted by T cell reinfusions resulting in durable remissions in patients with chronic myelogenous leukemia who have relapsed after an allogeneic transplant. Interleukin-2 is the primary growth factor for T lymphocytes and is a stimulator of natural killer cell activity. It has now been shown that a limited number of otherwise refractory leukemias can be effectively treated with interleukin-2. However, there remains a lack of correlation between the biologic and clinical effects of interleukin-2. The clinical activity of interleukin-2 appears to be greatest in myeloid leukemias. A variety of dose schedules and routes of administration make it difficult to determine if interleukin-2 given to patients in clinical remission is of benefit. Large randomized studies are necessary to explore the role of interleukin-2 in leukemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goodman, M., Cabral, L. & Cassileth, P. Interleukin-2 and leukemia. Leukemia 12, 1671–1675 (1998). https://doi.org/10.1038/sj.leu.2401199
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401199
Keywords
This article is cited by
-
Phosphorylation of CrkL S114 induced by common gamma chain cytokines and T-cell receptor signal transduction
Scientific Reports (2021)
-
Role of cytokines in the treatment of acute leukemias: a review
Leukemia (2006)
-
BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia
Oncogene (2002)
-
Leukemia vaccines
Current Oncology Reports (2001)
-
Treatment of leukemic relapse following unrelated umbilical cord blood transplantation with interleukin-2: potential for augmenting graft-versus-leukemia and graft-versus-host effects with cytokines
Bone Marrow Transplantation (2000)